|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
EP2935253B1
(en)
|
2012-12-21 |
2018-08-01 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
EP3010917B1
(en)
|
2013-06-21 |
2018-01-31 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
SI3010503T1
(sl)
|
2013-06-21 |
2020-07-31 |
Zenith Epigenetics Ltd. |
Novi biciklični inhibitorji bromodomene
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
EP3057586B1
(en)
|
2013-10-18 |
2019-12-04 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitors
|
|
NZ719465A
(en)
*
|
2013-11-26 |
2017-03-31 |
Gilead Sciences Inc |
Quinoline derivatives as bromodomain inhibitors
|
|
EP3080112B1
(en)
*
|
2013-12-09 |
2020-06-03 |
UCB Biopharma SRL |
Imidazopyridine derivatives as modulators of tnf activity
|
|
GB201321737D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
CA2966298A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
EP3227280B1
(en)
|
2014-12-01 |
2019-04-24 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
CA2966449A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
|
GB201503720D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
WO2016149668A1
(en)
|
2015-03-18 |
2016-09-22 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
*
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201506660D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
EP3331905B1
(en)
|
2015-08-06 |
2022-10-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US10836742B2
(en)
|
2015-08-11 |
2020-11-17 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
CN108290856A
(zh)
|
2015-08-11 |
2018-07-17 |
尼奥迈德研究所 |
芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
|
|
EP3334719B1
(en)
*
|
2015-08-12 |
2021-09-15 |
Neomed Institute |
Substituted benzimidazoles, their preparation and their use as pharmaceuticals
|
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
|
CN108602821B
(zh)
*
|
2015-12-14 |
2021-06-29 |
恒元生物医药科技(苏州)有限公司 |
1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂
|
|
US10519151B2
(en)
|
2016-01-28 |
2019-12-31 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
|
|
US10517877B2
(en)
|
2016-03-30 |
2019-12-31 |
Wisconsin Alumni Research Foundation |
Compounds and methods for modulating frataxin expression
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
GB201614939D0
(en)
*
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
WO2018106667A1
(en)
*
|
2016-12-05 |
2018-06-14 |
Microbiotix, Inc. |
Broad-spectrum inhibitors of filoviruses
|
|
CN111386263A
(zh)
|
2017-02-08 |
2020-07-07 |
达纳-法伯癌症研究所有限公司 |
调节嵌合抗原受体
|
|
US11759533B2
(en)
|
2017-03-29 |
2023-09-19 |
Wisconsin Alumni Research Foundation |
Methods and compositions for modulating gene expression
|
|
CN109111437B
(zh)
*
|
2017-06-22 |
2022-03-04 |
中国科学院广州生物医药与健康研究院 |
一种苯并[d]异恶唑类化合物及其制备方法和应用
|
|
CN109280046B
(zh)
*
|
2017-07-21 |
2021-02-02 |
浙江海正药业股份有限公司 |
苯并咪唑类衍生物及其制备方法及其在医药上的用途
|
|
EP3661926B1
(en)
*
|
2017-08-04 |
2022-02-23 |
Bristol-Myers Squibb Company |
Substituted indole compounds useful as inhibitors of tlr7/8/9
|
|
EP3743067A1
(en)
*
|
2018-01-25 |
2020-12-02 |
Boehringer Ingelheim International GmbH |
Combination treatment of acute myeloid leukemia
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
US10442799B1
(en)
|
2018-04-07 |
2019-10-15 |
Fuqiang Ruan |
Heterocyclic compounds and uses thereof
|
|
IL302595A
(en)
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
JP2022053557A
(ja)
*
|
2019-02-08 |
2022-04-06 |
マルホ株式会社 |
ピリドン誘導体
|
|
CA3152923A1
(en)
|
2019-09-30 |
2021-04-08 |
Keisuke Yamamoto |
Bet degrader
|
|
MX2022007678A
(es)
|
2019-12-19 |
2022-09-19 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
